Skip to main content

Drug combination therapy of systemic lupus erythematosus

  • Chapter
  • 120 Accesses

Abstract

During the past few decades, the survival of systemic lupus erythematosus (SLE) patients has steadily improved, so much so that it has become a minor issue with a mortality rate of approximately 1-2% per annum [2, 11]. The main problem today for lupus patients concerns their quality of life and the risk of loss of kidney function. Indeed, too many patients still lose this function (9% after 5 years of disease, 17% after 10 years) [2]. The aim of today’s management of SLE is thus centred on allowing patients a good quality of life in both professional and personal terms, including the possibility of having children.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beris P, Burger A, Favre L, Riondel A, Miescher PA (1986) Adrenocortical responsiveness after discontinuous corticosteroid therapy. Klin Wochenschr 64: 70

    Article  PubMed  CAS  Google Scholar 

  2. Esdaile JM (1994) Prognosis in systemic lupus erythematosus. Springer Semin Immunopathol 16: 337

    Article  PubMed  CAS  Google Scholar 

  3. Favre H (1973) Détermination des fonctions rénales par la technique de l’injection unique. Analyse statistique de modéle bicompartimental proposé par Sapirstein. J Urol Nephrol 79: 1007

    CAS  Google Scholar 

  4. Feutren G, Querin S, Tron F, Noel LH, Chatenoud L, Lesavre P, Bach JF (1986) The effects of cyclosporine in patients with systemic lupus. Transplant Proc 18: 643 factor: parameters of production and a quantitative microassay for activity. J Immunol 120: 2027

    Google Scholar 

  5. Horwitz DA, Jacob CO (1994) The role of cytokines in the pathogenesis of systemic lupus erythematosus. Springer Semin Immunopathol 16: 181

    Article  PubMed  CAS  Google Scholar 

  6. Huang YP, Miescher PA, Zubler RH (1986) The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol 137: 3515

    PubMed  CAS  Google Scholar 

  7. Huang YP, Perrin LH, Miescher PA, Zubler RH (1988) Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 141: 827

    PubMed  CAS  Google Scholar 

  8. Huang YP, Pechere JC, Michel M, Gauthey L, Loreto M, Curran JA, Michel JP (1992) In vivo T cell activation, in vitro defective IL-2 secretion, and response to influenza vaccination in elderly women. J Immunol 148: 715

    PubMed  CAS  Google Scholar 

  9. Izui S, Lambert PH, Miescher PA (1976) Deterruination of anti-DNA antibodies by a modified 125I-labelled DNA-binding test. Elimination of non-specific binding of DNA to non-immunoglobulin basic proteins by using an anionic detergent. Clin Exp Immunol 26: 423

    Google Scholar 

  10. McLaughlin J, Gladman DD, Urowitz MB, Bombardier C, Farewell VT, Cole E (1991) Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. Arthritis Rheum 34: 1268

    Article  PubMed  CAS  Google Scholar 

  11. Miescher PA, Favre H, Chatelanat F, Mihatsch MJ (1987) Combined steroid-cyclosporin treatment of chronic autoimmune diseases. Klin Wochenschr 65: 727

    Article  PubMed  CAS  Google Scholar 

  12. Miescher PA, Huang YP, Zubler RH (1988) New approaches to the treatment of RA. Springer Semin Immunopathol 10: 251

    Article  PubMed  CAS  Google Scholar 

  13. Perrin LH, Lambert PH, Nydegger U, Miescher PA (1973) Quantitation of C3PA and other complement components in diseases associated with a low C3 level. Clin Immunol Immunopathol 2: 16

    Article  PubMed  CAS  Google Scholar 

  14. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172

    PubMed  CAS  Google Scholar 

  15. Steinberg AD, Steinberg S (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34: 945

    Article  PubMed  CAS  Google Scholar 

  16. Waldmann TA (1993) The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 14: 264

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Miescher, P.A., Favre, H., Lemoine, R., Huang, YP. (1995). Drug combination therapy of systemic lupus erythematosus. In: Miescher, P.A. (eds) Systemic Lupus Erythematosus. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79622-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79622-7_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79624-1

  • Online ISBN: 978-3-642-79622-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics